About Enthera
Enthera is a company based in Milano (Italy) founded in 2016 by Gabriella Camboni. Enthera has raised $45.91 million across 3 funding rounds from investors including AbbVie, Sofinnova Partners and T1D Fund. Enthera offers products and services including Ent001 and Monoclonal Antibodies. Enthera operates in a competitive market with competitors including Moderna, Aclaris Therapeutics, Horizon Therapeutics, Forge Biologics and argenx, among others.
- Headquarter Milano, Italy
- Founders Gabriella Camboni
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Enthera Srl
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$45.91 M (USD)
in 3 rounds
-
Latest Funding Round
$8.49 M (USD), Series A
Jan 28, 2021
-
Investors
AbbVie
& 4 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Enthera
Enthera offers a comprehensive portfolio of products and services, including Ent001 and Monoclonal Antibodies.
Antibody targeting TMEM219 for Ulcerative Colitis treatment
Libraries of antibodies for IGFBP3/TMEM219 pathway in autoimmune diseases
People of Enthera
Unlock access to complete
Unlock access to complete
Funding Insights of Enthera
Enthera has successfully raised a total of $45.91M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $8.49 million completed in January 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Enthera
Enthera has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include AbbVie, Sofinnova Partners and T1D Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Sofinnova Partners is focused on life sciences and healthcare investments.
|
Locked | Locked | Locked | |
|
Companies developing T1D products are funded through venture philanthropy.
|
Locked | Locked | Locked | |
|
Corporate-backed venture capital firm focused on the healthcare sector
|
Locked | Locked | Locked |
Investor details for Enthera
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Enthera
Investment portfolio details for Enthera
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Enthera
Detailed financials for Enthera
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Enthera Comparisons
Peer comparison for Enthera
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Enthera
Enthera operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Aclaris Therapeutics, Horizon Therapeutics, Forge Biologics and argenx, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Novel dermatologic therapies are developed for skin conditions.
|
|
| Locked | Locked | Locked |
Developer of drugs for treating rare and autoimmune diseases
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases are developed to treat patients.
|
|
| Locked | Locked | Locked |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment.
|
|
| Locked | Locked | Locked |
Genetically engineered cell therapies are developed for multiple disorders.
|
Detailed competitors of Enthera
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Enthera
Complete news archive for Enthera
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Enthera
Enthera was founded in 2016 and raised its 1st funding round 2 years after it was founded.
Enthera is headquartered in Milano, Italy.
Giovanni Amabile is the current CEO of Enthera.
Enthera is a funded company, having raised a total of $45.91M across 3 funding rounds to date.
Enthera was founded in 2016 in Milano, Italy, where biotherapeutics targeting auto-immune disorders, including type-1 diabetes, are developed. Focus is placed on the IGFBP3TMEM219 pathway, which influences stem cell apoptosis in these conditions. A proprietary discovery engine is utilized to generate libraries of monoclonal antibodies and fusion proteins. Operations center on advancing pipeline products for therapeutic applications in the biotechnology sector.
Enthera's top competitors include Moderna, argenx and Forge Biologics.
Enthera offers Ent001 and Monoclonal Antibodies.
Enthera has 5 investors. Key investors include AbbVie, Sofinnova Partners, T1D Fund, Roche, and Banor.